denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Description:
This session will address the role the tumor microenvironment plays in lymphoid malignancies and how disrupting the pro-tumorigenic niche (or microenvironment) including the immune checkpoint network provides a new weapon against cancer. Recent translational discoveries with checkpoint inhibitors have the potential to unleash anti-tumor immunity in populations (or subsets) of patients with lymphoid malignancies.
Dr. Steidl will give an overview on the tumor microenvironment and present his data on biomarkers and acquired immune privilege.
Dr. Ramsay will discuss immune checkpoint signalling axes including PD-L1, CTLA-4 in the tumor microenvironment and related immune evasion mechanisms.
Dr. Ansell will focus on clinical trial results with PD-1 and CTLA4 directed antibodies in non-Hodgkin lymphoma and Hodgkin’s disease.